PAVmed (PAVM) Prices Additional $8.1 Million Common Stock Registered Direct Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- US stock futures steady after tech slump; investors focus on Middle East tensions
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Marvell shares jump after giving Google warrants amid custom chip deal
PAVmed Announces Pricing of Additional $8.1 Million Common Stock Registered Direct Offering
December 18, 2020 9:29 AM ESTNEW YORK, Dec. 18, 2020 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the Company or PAVmed), a highly differentiated, multi-product, commercial-stage medical device company, today announced it has entered into agreements for the sale of approximately 5.1 million shares of common stock in a registered direct offering with predominantly existing institutional investors at a price of $1.60 per share for gross proceeds of $8.1 million.
The estimated net proceeds to PAVmed from the registered direct offering are expected to be approximately $7.4 million after deducting the placement agents fees and other estimated offering expenses. The offering is expected to close on or... More
